Dow to Unveil Beauty & Personal Care Products

Zacks

The Dow Chemical Company (DOW) recently announced that it will showcase two new products that that help in facilitating exciting features in skin care and cleansing formulations. These products will be showcased at the New York Society of Cosmetic Chemists (:NYSCC) Suppliers’ Day in Edison, NJ on May 13 and 14.

One of the products to be showcased is EcoSmooth Delight, a novel sensorial enhancer which offers formulators a new, broadly compatible toolkit to provide consumers with a premium sensory experience at an affordable cost. It helps the formulators to create spa-like skin care products that are non-tacky and non-greasy.

EcoSmooth Delight also provide the consumers with a feel-good factor with a lasting impression of luxury. It helps formulators attain an elevated sensorial performance extremely close to that of silicone elastomers at a much lower cost, thereby catering to the masses for skin care.

The other product that will be showcased, at the NYSCC, is ACULYN Excel Rheology Modifier, which is a new suspension aid that helps formulators to suspend beads and capsules that help deliver specialized beauty benefits, such as moisturizing, exfoliating or anti-aging  – while also performing well at very low pH levels of five and below.

With these products Dow can offer its customers an even richer experience, leading to brand differentiation and exciting growth opportunities.

Dow’s shares rose 0.8% in the trading session last Wednesday. The stock is up roughly 12% so far this year.

Dow currently holds a Zacks Rank #2 (Buy).

Other companies in the chemical industry worth considering include Compass Minerals International Inc. (CMP), L'Air Liquide SA (AIQUY) and Kronos Worldwide, Inc. (KRO). While Compass Minerals carries a Zacks Rank #1 (Strong Buy), L'Air Liquide and Kronos retain a Zacks Rank #2 (Buy).

Read the Full Research Report on DOW
Read the Full Research Report on AIQUY
Read the Full Research Report on KRO
Read the Full Research Report on CMP


Zacks Investment Research

Rates

View Comments (0)